Genzyme Completes Acquisition Of Ilex, Awaits Clolar Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme closes $1 bil. deal the day after receiving Federal Trade Commission approval. Clolar could be Genzyme's first direct presence in oncology therapeutic market; FDA's user fee deadline is Dec. 30.